Vitamin D status and bone density in steroid-treated children with glomerulopathies: effect of cholecalciferol and calcium supplementation.
The aim of this study was to assess vitamin D status and bone density in steroid-treated children with glomerulopathies and to evaluate the effect of prophylactic vitamin D and calcium supplementation. Retrospective analysis was performed on 55 children aged 4-18 yrs with glomerulopathies. The following data were analyzed: antropometrical parameters, bone densitometries, parathormone, 25-hydroxyvitamin D (25-OHD), urinary calcium excretion and medications received for prevention of low bone mass. A significant number of children (38%) had decreased spinal bone mineral density (BMD z-score < -2.0) and the majority of them (89%) had hypovitaminosis D (25-OHD < 30 ng/ml), 75% were vitamin D insufficient (25-OHD < 20 ng/ml) and 16% were vitamin D deficient (25-OHD < 10 ng/ml). The mean serum 25-OHD concentration was comparable to that of controls (19.32 ± 12.87 vs. 15.05 ± 8.52 ng/ml). Nearly all patients (82%) were receiving preparations of calcium and/or vitamin D to improve bone health. Patients on cholecalciferol had higher mean concentration of 25-OHD compared to those who were not receiving it (p=0.027) and to the controls (p=0.047). In 23 children on vitamin D and calcium supplementation for an average 6-month time, we observed an increase in the mean BMD values (p=0.004), however, mean BMD z-score and 25-OHD concentrations did not significantly change over time. Vitamin D and bone density deficits are remarkably common in steroid-treated children with glomerulopathies, despite vitamin D and calcium repletion. In order to enhance the effectiveness of vitamin D supplementation for improvement of bone density, we suggest regular assessment of serum concentration of 25-OHD that can guide subsequent dose adjustment of vitamin D.